While gallbladder-related issues are less common compared to other gastrointestinal side effects, they can cause significant discomfort for some patients, particularly during the dose-escalation phase and periods of rapid weight loss
Here we review published data from 24-h time-averaged HR monitoring in healthy individuals and subjects with type 2 diabetes mellitus (T2DM) treated with either short-acting GLP-1 RAs, lixisenatide or exenatide, or long-acting GLP-1 RAs, exenatide LAR, liraglutide, albiglutide, or dulaglutide (N = 1112
Diabetes Care 2006;29:471
Reactive astrocytes: production, function, and therapeutic potential
Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal T-cell number: A prospective case-series study